MétaCan
Menu
Back to cohort
Record W4414963895 · doi:10.1136/gutjnl-2025-basl.44

P28 Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival

2025· article· en· W4414963895 on OpenAlexaff
Bettina E. Hansen, Louise Missen, Susheela Carroll, Yanlai Zhou, F J Montero Pérez, Gideon M. Hirschfield

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsToronto General HospitalToronto Liver CentreUniversity of Toronto
Fundersnot available
KeywordsUrsodeoxycholic acidPlaceboConfidence intervalClinical endpointBilirubinOverall survival

Abstract

fetched live from OpenAlex

The GLOBE score is a validated risk-assessment tool used to estimate transplant-free survival (TFS) in patients with primary biliary cholangitis (PBC). Seladelpar is a first-in-class delpar (selective PPAR-delta agonist) indicated in the UK for PBC treatment including pruritus combined with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients intolerant to UDCA. This analysis evaluated the change in GLOBE score in patients with PBC on seladelpar from the placebo-controlled Phase 3 RESPONSE (NCT04620733) trial and its open-label extension (ASSURE; NCT03301506). Patients with PBC who received UDCA for ≥12 months (M) or were intolerant to UDCA, and had alkaline phosphatase (ALP) ≥1.67 × the upper limit of normal (ULN) and total bilirubin (TB) ≤2 × ULN were enrolled into RESPONSE and randomised 2:1 to daily seladelpar 10 mg or placebo. After 1 year (Y), patients were eligible for ASSURE, where patients on placebo could switch to seladelpar (crossover) and patients on seladelpar continued treatment (continuous). Change in GLOBE score, predicted TFS, and the contributions of ALP, TB, albumin, and platelets to changes in GLOBE score were evaluated. 193 patients were enrolled. Baseline characteristics were balanced between groups; 95% were female; mean (SD) age and duration of PBC were 57 (9.7) and 8 (6.6) years. Mean (SD) baseline values were 314 (120.9) U/L for ALP, 0.76 (0.31) mg/dL for TB, 4.1 (0.26) g/dL for albumin, 242 (80.6) × 103/uL for platelets, and 0.32 (0.68) for GLOBE score. Mean (SD) changes in baseline GLOBE score at 3M and 1Y for seladelpar were −0.38 (0.21) and −0.34 (0.39) vs −0.07 (0.28) and −0.01 (0.32) for placebo. At 2Y, GLOBE score changes were −0.39 (0.33) and −0.42 (0.50) for continuous or crossover seladelpar. For seladelpar, the greatest changes in GLOBE score were attributable to the ALP component (3M, −0.20; 1Y, −0.21; 2Y, −0.19), followed by the TB component (3M, −0.11; 1Y, −0.09; 2Y, −0.13). Seladelpar treatment for 3M, 1Y, and 2Y led to predicted changes in TFS with hazard ratios (HR; [95% CIs]) of 0.7 (0.7–0.7), 0.8 (0.7–0.9), and 0.7 (0.6–0.8) compared with baseline. HR (95% CIs) for placebo at 3M and 1Y were 1.0 (0.9–1.0) and 1.0 (1.0–1.1). At 2Y, crossover seladelpar had similar results to continuous seladelpar. Seladelpar resulted in an early decrease in GLOBE score for patients with PBC, which was maintained over 2Y and associated with improved predicted TFS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.210
Teacher spread0.202 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same topicLiver Diseases and ImmunityFrench-language works237,207